For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Alprostadil - Erectile dysfunction
PAD Profile : Alprostadil - Erectile dysfunction Important
Traffic Light Status
Status 1 of 3.
- Cream
Status 2 of 3.
- Intraurethral
Status 3 of 3.
Guidelines
The following guidelines are available for this indication.
Other Drugs
Other Indications
Additional Documents
Committee Recommendations
Alprostadil intra-urethral applications may be initiated in primary care following specialist recommendation.
The patient must have been provided with, or directed to, training materials to support self-administration before prescribing is requested from the GP.
Alprostadil intracavernosal injections should be initiated in secondary care, patients trained to self-administer and treatment shown to be effective before discharge for GPs to prescribe.
Alprostadil cream (Vitaros) is restricted by SLS criteria as identified in the Health Service Circular (HSC) 1999/148 at a maximum frequency of dosing of four times per month.
Alprostadil cream (Vitaros®) is a treatment option in primary care for patients who do not respond to PDE-5 inhibitors. This can be initiated in primary care and is considered GREEN on the traffic light system
Combination treatments (oral & non oral)
These treatments should not be used in combination with other treatments for erectile dysfunction due to the limited evidence available to support their use.